Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Radiother ; 26(1-2): 298-308, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34955418

RESUMO

External beam radiotherapy and brachytherapy are major treatments in the management of cervical cancer. For early-stage tumours with local risk factors, brachytherapy is a preoperative option. Postoperative radiotherapy is indicated according to histopathological criteria. For advanced local tumours, chemoradiation is the standard treatment, followed by brachytherapy boost, which is not optional. We present the update of the recommendations of the French Society of Oncological Radiotherapy on the indications and techniques for external beam radiotherapy and brachytherapy for cervical cancer.


Assuntos
Neoplasias do Colo do Útero/radioterapia , Braquiterapia/métodos , Quimiorradioterapia , Quimioterapia Adjuvante , Feminino , França , Humanos , Estadiamento de Neoplasias/classificação , Órgãos em Risco/diagnóstico por imagem , Posicionamento do Paciente , Cuidados Pós-Operatórios , Cuidados Pré-Operatórios/métodos , Radioterapia (Especialidade) , Terapia de Salvação , Carga Tumoral , Neoplasias do Colo do Útero/diagnóstico por imagem , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/terapia
2.
Cancer Radiother ; 23(8): 847-852, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31375324

RESUMO

PURPOSE: Brachytherapy can be used for the treatment of every localized prostate cancer, notably as boost for intermediate- and high-risk prostate cancer. With the incidence of prostate cancer increasing significantly during the next decades and brachytherapy developing, we conducted a descriptive survey to analyse the current status of prostate brachytherapy in France to see if the future demands could be met. MATERIAL AND METHODS: All radiotherapy centres that declared providing brachytherapy were found from the French national institute of cancer registry and they were asked to reply to an online form in April 2018. RESULTS: Fifty-two of the 54-brachytherapy centres (96%) replied the form and 34 centres did prostate brachytherapy. Among those centres, 32 performed iodine 125 low-dose rate brachytherapy as monotherapy, 19 provided brachytherapy boost (eight centres low-dose rate 125I; seven centres high-dose rate; four centres both). Among the centres not performing brachytherapy boost, 18 wanted to do, eight did not want and nine did not reply. The main reasons for reluctance towards brachytherapy boost were: organization constraints (three centres), refer patients to a nearby brachytherapy centre (one centre), technical issues (two centres) and lack of strong scientific evidences (two centres). In terms of human resources, the mean number of trained physicians and physicists were two (range: 1-6) and three (range: 1-5) respectively. CONCLUSION: In France, the future needs for prostate brachytherapy cannot be met by the current health supply. Health authorities should firstly reimburse brachytherapy boost and redefine an optimal training and organization of centres such that every patient with prostate cancer can receive optimal treatment.


Assuntos
Braquiterapia/estatística & dados numéricos , Institutos de Câncer/estatística & dados numéricos , Neoplasias da Próstata/radioterapia , Institutos de Câncer/provisão & distribuição , França , Pesquisas sobre Atenção à Saúde/estatística & dados numéricos , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Neoplasias da Próstata/patologia , Dosagem Radioterapêutica , Radioterapia Adjuvante/estatística & dados numéricos
3.
Cancer Radiother ; 21(6-7): 521-526, 2017 Oct.
Artigo em Francês | MEDLINE | ID: mdl-28826697

RESUMO

Locoregional relapse in previously irradiated region for head and neck tumours is associated with a bad locoregional and distant prognosis. Reirradiation might be exclusive, or feasible in addition with surgery and/or chemotherapy, according to histopronostic factors. Data show that reirradiation is feasible with some severe toxicity due to the bad prognosis of this situation. Hyperfractionnated regimen with split course or normofractionnated regimen without split course are possible with similar efficacy. If tumour size is small, stereotactic ablative radiotherapy may be considered, and if the treatment centre has proton therapy, it could be proposed because of better organs at risk sparing. There is no standard regarding reirradiation schedules and several trials have to be done in order to determine the best technique. Nevertheless, it is agreed that a total dose of 60Gy (2Gy per fraction) is needed. Other trials testing the association with new systemic agents have to be performed, among them agents targeting the PD1/PD-L1 axis.


Assuntos
Neoplasias de Cabeça e Pescoço/radioterapia , Reirradiação , Carcinoma de Células Escamosas/radioterapia , Humanos , Dosagem Radioterapêutica
4.
Cancer Radiother ; 20(6-7): 587-94, 2016 Oct.
Artigo em Francês | MEDLINE | ID: mdl-27614526

RESUMO

Accelerated Partial Breast Irradiation (APBI) appears to be an efficient therapeutic modality provided that it uses strict selection criteria and a reliable and well-managed technique. The techniques that enable to deliver postoperative APBI are interstitial brachytherapy, endocavitary brachytherapy and external beam radiation therapy. Once an appropriate selection of the candidates is made, each radiation technique needs an exact target volume definition and a strict compliance with its own dosimetric constraints. Results of ongoing randomized trials should increase our knowledge of all these parameters, and give us responses about the comparison of the different techniques.


Assuntos
Braquiterapia/métodos , Neoplasias da Mama/radioterapia , Radioterapia Conformacional/métodos , Feminino , Humanos , Seleção de Pacientes , Dosagem Radioterapêutica , Radioterapia Adjuvante , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...